July 3, 2017 — IBA and Philips announced in mid-June they are stepping up their combined effort for proton therapy in Brazil.
Both companies agreed to escalate joint sales and marketing activities in Brazil, for the promotion of Philips's imaging and clinical informatics solutions in oncology, and IBA's proton therapy solutions. The agreement merges their respective expertise in image guidance and therapy with the ultimate objective of enabling more effective and personalized cancer care.
The Brazilian market for superior medical imaging solutions and advanced forms of radiotherapy treatment such as proton therapy is a key focus for both partners. The commercial collaboration between Philips and IBA has already led to the successful execution of proton therapy contracts in Europe, Asia and the Middle-East.
The two companies offer unique integrated solutions for proton therapy and molecular imaging centers. They are currently installing state-of-the-art proton therapy solutions at three compact proton therapy centers in the U.K., one compact center in the Middle East, and one large proton therapy center in India. Depending on the proton therapy center, the installed solution can include IBA’s proton therapy systems, such as; the Proteus One and Proteus Plus, and Philips’ imaging and clinical informatics solutions, such as Philips’ Big Bore CT (computed tomography) and positron emission tomography (PET)/CT systems and Philips’ Pinnacle3 Treatment Planning System.
For more information: www.iba-worldwide.com, www.usa.philips.com/healthcare
April 25, 2024 
